Filter By Category
Archives
Share on -
CABAZITAXEL(JEVTANA)
Generic Name: CABAZITAXEL(JEVTANA)
ABSTRACT -
Cabazitaxel (Jevtana) is a semi-synthetic taxane cytotoxic agent approved for hormone-refractory metastatic prostate cancer previously treated with docetaxel. It binds to tubulin and promotes microtubule assembly while inhibiting disassembly, arresting cell division and inducing apoptosis. Unlike docetaxel, cabazitaxel has limited affinity for P-glycoprotein, enabling activity in multidrug-resistant tumours.
DOSAGE -
20–25 mg/m² intravenously over 1 hour every 3 weeks in combination with oral prednisone 10 mg daily; premedication with antihistamine, corticosteroid, and H2 antagonist required.
SIDE EFFECTS-
- Neutropenia (severe)
- Diarrhoea
- Fatigue
- Nausea and vomiting
- Anaemia and thrombocytopenia
ALLERGIC REACTIONS -
These symptoms may indicate an allergic reaction and require immediate medical attention.
- Hypersensitivity reactions (despite premedication)
- Urticaria
- Hypotension
- Bronchospasm
DRUG INTERACTIONS-
- Avoid strong CYP3A4 inhibitors (ketoconazole, clarithromycin)
- Strong CYP3A4 inducers reduce efficacy (rifampicin, St John's Wort)
- Concomitant myelosuppressive drugs increase toxicity
PREAUTONS–
- G-CSF prophylaxis recommended for febrile neutropenia risk patients
- Hepatic impairment: contraindicated if bilirubin >3× ULN
- Renal monitoring required
- Polysorbate 80-based formulation — check for hypersensitivity
WARNINGS –
- Severe neutropenia and febrile neutropenia are common — weekly CBC monitoring required
- GI toxicity including fatal enterocolitis reported
- Contraindicated in neutrophil count <1500 cells/mm³
Share on -
. Developed by